“Pfizer has announced it will stop enrollment in a clinical trial for Paxlovid - its COVID-19 antiviral pill - for standard-risk COVID-19 patients after the latest results suggested the drug did not reduce symptoms or hospitalizations and deaths to a statistically significant degree.”
Read Our Latest News
Do you like this post?
Showing 1 reaction
Sign in with